Skip to content

Study · Observational study · n = 2,054 · 2021

6 results

Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis.

Guo CL, Mei JD, Jia YL, Gan FY, Tang YD, Liu CW, Zeng Z, Yang ZY, Deng SY, Sun X, Liu LX

Chinese medical journal3 Nov 2021Cited by 17 (Europe PMC)

PMID34732663 (opens in a new tab)PMCIDPMC8631386 (opens in a new tab)DOI10.1097/cm9.0000000000001819 (opens in a new tab)PepBankPUB-34732663
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In propensity score-matched patients with resected NSCLC, 5-year disease-free survival was significantly higher in the Tα1 group than in the control group.

    In plain wordsIn people with resected lung cancer, five-year survival without recurrence was higher with thymosin α1 than without it.

    Peptide
    Thymosin alpha-1
    Outcome
    Increase5-year disease-free survival
    Study

    n = 2,054

    Comparator
    Control group without Tα1
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The 5-year disease-free survival (DFS) and overall survival (OS) rates were significantly higher in the Tα1 group compared with the control group.
    1 context sentence
    Summary · context
    The patients were divided into the Tα1 group and the control group according to whether they received Tα1 or not. A propensity score matching (PSM) analysis was performed to reduce bias, resulting in 1027 pairs of patients.
  2. 02HumanObservational studyEfficacy outcome

    In propensity score-matched patients with resected NSCLC, 5-year overall survival was significantly higher in the Tα1 group than in the control group.

    In plain wordsIn people with resected lung cancer, five-year overall survival was higher with thymosin α1 than without it.

    Peptide
    Thymosin alpha-1
    Outcome
    Increase5-year overall survival
    Study

    n = 2,054

    Comparator
    Control group without Tα1
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The 5-year disease-free survival (DFS) and overall survival (OS) rates were significantly higher in the Tα1 group compared with the control group.
    1 context sentence
    Summary · context
    The patients were divided into the Tα1 group and the control group according to whether they received Tα1 or not. A propensity score matching (PSM) analysis was performed to reduce bias, resulting in 1027 pairs of patients.
  3. 03HumanObservational studyEfficacy outcome

    In multivariable analysis, Tα1 treatment was independently associated with an improved prognosis in patients with resected NSCLC.

    In plain wordsAfter adjusting for other factors, thymosin α1 treatment was linked to a better outlook in people with resected lung cancer.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedIndependent association with prognosis
    Study

    n = 2,054

    Comparator
    Control group without Tα1
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The multivariable analysis showed that Tα1 treatment was independently associated with an improved prognosis.
    1 context sentence
    Summary · context
    The patients were divided into the Tα1 group and the control group according to whether they received Tα1 or not. A propensity score matching (PSM) analysis was performed to reduce bias, resulting in 1027 pairs of patients.
  4. 04HumanObservational studyEfficacy outcome

    In subgroup analyses by age, sex, CCI, smoking status and TNM stage, Tα1 therapy was associated with improved DFS and/or OS, especially in non-squamous NSCLC and without targeted therapy.

    In plain wordsIn most patient subgroups with resected lung cancer, thymosin α1 was linked to better survival, especially in non-squamous disease without targeted therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival in subgroups
    Study

    n = 2,054

    Comparator
    Control group without Tα1
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The subgroup analyses showed that Tα1 therapy could improve the DFS and/or OS in all subgroups of age, sex, Charlson Comorbidity Index (CCI), smoking status, and pathological tumor-node-metastasis (TNM) stage, especially for patients with non-squamous cell NSCLC and without targeted therapy.
    1 context sentence
    Summary · context
    The patients were divided into the Tα1 group and the control group according to whether they received Tα1 or not. A propensity score matching (PSM) analysis was performed to reduce bias, resulting in 1027 pairs of patients.
  5. 05HumanObservational studyEfficacy outcome

    A longer duration of Tα1 treatment was associated with improved overall survival in patients with resected NSCLC.

    In plain wordsIn people with resected lung cancer, longer thymosin α1 treatment was linked to longer overall survival.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTreatment duration and overall survival
    Study

    n: not reported in source

    Comparator
    Control group without Tα1
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A longer duration of Tα1 treatment was associated with improved OS and DFS.
    1 context sentence
    Summary · context
    The patients were divided into the Tα1 group and the control group according to whether they received Tα1 or not. A propensity score matching (PSM) analysis was performed to reduce bias, resulting in 1027 pairs of patients.
  6. 06HumanObservational studyEfficacy outcome

    A longer duration of Tα1 treatment was associated with improved disease-free survival in patients with resected NSCLC.

    In plain wordsIn people with resected lung cancer, longer thymosin α1 treatment was linked to longer survival without recurrence.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTreatment duration and disease-free survival
    Study

    n: not reported in source

    Comparator
    Control group without Tα1
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A longer duration of Tα1 treatment was associated with improved OS and DFS.
    1 context sentence
    Summary · context
    The patients were divided into the Tα1 group and the control group according to whether they received Tα1 or not. A propensity score matching (PSM) analysis was performed to reduce bias, resulting in 1027 pairs of patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.